Human jejunal permeability of cyclosporin A: Influence of surfactants on P-glycoprotein efflux in Caco-2 cells

被引:91
作者
Chiu, YY
Higaki, K
Neudeck, BL
Barnett, JL
Welage, LS
Amidon, GL
机构
[1] Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA
[2] Okayama Univ, Fac Pharmaceut Sci, Dept Pharmaceut, Okayama 7008350, Japan
[3] Univ Michigan, Univ Hosp, Serv Pharm, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Med Ctr, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI 48109 USA
关键词
intestinal permeability; P-glycoprotein; cyclosporin A; biopharmaceutic classification system; Caco-2 cell culture; MICROEMULSION FORMULATION; HEALTHY-SUBJECTS; PHARMACOKINETICS; TRANSPORT; DRUG; BIOAVAILABILITY; PROPRANOLOL; ABSORPTION; SANDIMMUN; BEHAVIOR;
D O I
10.1023/A:1023481418576
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. The purpose of this work was to determine the jejunal permeability of cyclosporin A (CsA) in humans and whether formulation variables modulate the effects of P-glycoprotein (P-gp) on the permeability of CsA in Caco-2 cells. Methods. A solution containing CsA, phenylalanine, propranolol, polyethyleneglycol ( PEG) 400, and PEG 4000 was perfused through a 10-cm jejunal segment in 12 subjects. Caco-2 transport studies were performed using previously reported methodology. Results. The mean P-eff (+/-SD) of CsA in humans was 1.65 (0.53). The mean permeabilities for phenylalanine, propranolol, and PEG 400 were 4.54 (2.39), 2.90 (1.28), and 0.83 (0.51) x 10(-4) cm/s, respectively. The presence of surfactants significantly decreased the permeabilities of CsA in both directions in Caco-2 cells. Conclusions. The results suggest that the effects of surfactants via micellar solubilization and inhibition of P-gp efflux on CsA transport in Caco-2 cells are significant. CsA can rightly be classified as a low solubility-high permeability Class II BCS drug and its highly variable absorption from Sandimmune(R) oral formulations is the result of poor dissolution characteristics.
引用
收藏
页码:749 / 756
页数:8
相关论文
共 31 条
[31]   NONINVASIVE TESTS OF CYP3A ENZYMES [J].
WATKINS, PB .
PHARMACOGENETICS, 1994, 4 (04) :171-184